|
|
CD8 Response to Ritonavir
Abstract 451
CD8+ Lymphocyte Responses to Antiretroviral Therapy of HIV Infection.
Authors: A Carr, S Emery, A Kelleher, M Law and D Cooper.
Dr. David Cooper of University of New South Wales in Sydney, Australia, reported the effect of ritonavir on CD8 cell responses in patients enrolled in a dose comparison trial (protocol M93-112).
CD8 cells are important in controlling HIV infection by HLA-mediated cytotoxicity and production of soluble HIV suppressor factor. CD8 cells are typically elevated during HIV seroconversion and remain elevated for many years. Declines in CD8 cells are common with progression of HIV disease.
Ritonavir caused a dose-dependent peak increase of 892 CD8 cells/mm3 which remained significantly above baseline for 40 weeks in the higher dose groups. There was a significant correlation between the peak CD4 cells and response in CD8 cells to therapy. Dr. Cooper and colleagues concluded by saying that increases in CD8 cell proliferation induced by protease inhibitor could result in improved suppression of HIV replication by the immune system and result in improved suppression of latent viral and parasitic infections associated with opportunistic infections. However, the clinical significance of the CD8 cell increases observed with protease inhibitor therapy remains to be determined.
Go to the Abbott Update Menu
Go to the HIV Protease Inhibitor Report Menu
Go to the Protease Inhibitor Menu
Go to the HIVpositive.us Main Menu
39